placebo + botulinum toxin-Assistance Publique - Hôpitaux de Paris-hemiparesis

placebo + botulinum toxin-Assistance Publique - Hôpitaux de Paris-hemiparesis refers to a specific clinical trial intervention regimen evaluated in the GENUFLEX trial (NCT02293538), sponsored by Assistance Publique - Hôpitaux de Paris (AP-HP). The regimen utilizes Xeomin (incobotulinumtoxinA), a botulinum neurotoxin type A that is free from complexing proteins, to treat chronic hemiparesis following stroke or traumatic brain injury. The treatment involves intramuscular injections into the rectus femoris and plantar flexor muscles (such as the soleus) to address gait slowness and insufficient hip flexion. By cleaving the SNAP-25 protein, incobotulinumtoxinA prevents the release of acetylcholine from motor nerve endings, leading to localized muscle relaxation and improved gait function. The trial specifically compares the efficacy of combined muscle blocks (active toxin in both rectus femoris and plantar flexors) against distal blocks only (active toxin in plantar flexors and placebo in the rectus femoris).

Brand names

Xeomin

Other names

incobotulinumtoxinABotulinum toxin type ABotulinum neurotoxin type Aincobotulinumtoxin A